History

Taivex Therapeutics Corporation (TTC), founded in 2010, is focus on the development of "Novel", "Niche" and "Targeting" anti-cancer drugs. We are original invested by Taivex, LLC in California which is launched by Dr. Johnson Y.N. Lau. The core proprietary technology platform of Taivex is to identify compounds that inhibit the Hec1-Nek2 interaction which is authorized by Univ. Texas, San Antonio. After combination with the two key techniques: ”Methods and Compounds for inhibiting HEC1 for the Treatment of Proliferative Diseases” and ”Methods and Compounds for inhibiting Rad51 for the Treatment of Proliferative Diseases “, TTC will work on the development of new anti-cancer drugs in Taiwan. The company is also led by the experienced management team and looks forward the success in new drug development.

History:
    2015. Apr - The patent of " Modulators Of HEC1 Activity And Methods Therefor" (2nd generation compound) in USA has been Issued.


    2015. Feb - The patent of " Modulators Of HEC1 Activity And Methods Therefor" in USA has been Issued.


    2014. Sep - The patent of " Modulators Of HEC1 Activity And Methods Therefor" in Australia has been Issued.


    2014. Aug - The patent of " Modulators Of HEC1 Activity And Methods Therefor" in New Zealand has been approved.


    2012. Nov - Apply for Taiwan patent: " Modulators Of HEC1 Activity And Methods Therefor ".


    2012. Nov - Apply for US, PCT patent: " Modulators Of HEC1 Activity And Methods Therefor".


    2012. Nov - Apply for US, PCT patent: "Biomarkers for Cancers responsive to Modulators Of HEC1 activity".


    2012. Nov - Apply for Taiwan patent: "Biomarkers for Cancers responsive to Modulators of HEC1 activity".


    2011. Dec - The project "Nek2 / Hecl inhibitor of first-in-class anti-cancer drug" which is collaborated with DCB won the annual Breakthrough Innovation prize (Group) of the first Industry Innovation Award.


    2011. Q3 – Developed the IND candidate drug “T-1101”


    2010. Sep - Stationed into the Biotechnology Incubation Center of Ministry of Economic Affairs


    2010. Feb - Collaborate with DCB to develop the Hec1 project


    2009. Oct - The office of Taivex Therapeutics Corporation (TTC) was established in Taiwan in 2009 and the initial preparatory Address was
            4F., No.51, Sec. 2, Chongqing S. Rd., Zhongzheng Dist., Taipei City 100,Taiwan (R.O.C.)